Advertisement

Organisation › Details
Achilles Therapeutics (Group)
Achilles Therapeutics is a clinical stage, biopharmaceutical company developing personalised T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase 1/2a trials, the THETIS trial in patients with recurrent or metastatic malignant melanoma and the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC). Achilles uses DNA sequencing data from each patient, together with the proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop personalised T cell-based therapies specifically targeting those clonal neoantigens. Achilles was founded in 2016 by lead investor Syncona Ltd and is supported by an international syndicate of life science investors including RA Capital, Forbion, Invus, Perceptive Advisors, Redmile Group, OrbiMed and Boxer Capital of Tavistock Group. *
![]() |
Start | 2016-10-03 renamed |
Today | Achilles Therapeutics Ltd. | |
Predecessor | Achilles TX Ltd. | |
![]() |
Industry | T cell therapy |
Industry 2 | cancer drug | |
![]() |
Person | Ali, Iraj (Achilles Therapeutics 201812– CEO before Interim CEO + Syncona + McKinsey) |
![]() |
Region | London, Greater London |
Country | United Kingdom (GB) | |
Street | 245 Hammersmith Road | |
City | W6 8PW London | |
Tel | +44-20-8154-4600 | |
Address record changed: 2024-09-28 | ||
Basic data | Employees | D: 101 to 500 (2023-12-31) |
Currency | USD | |
Annual sales | 6,081,000 (income, other, total, consolidated (2023) 2023-12-31) | |
Profit | -69,665,000 (2023-12-31) | |
Cash | 131,539,000 (2023-12-31) | |
* Document for »About Section«: Achilles Therapeutics Ltd.. (11/19/20). "Press Release: Achilles Therapeutics Raises £52.7 Million in an Oversubscribed Series C Financing to Further Advance the Development of Personalised T cell Therapies to Treat Solid Tumours". Stevenage. | ||
Record changed: 2024-09-28 |
Advertisement

More documents for Achilles Therapeutics (Group)
- [1] Amphista Therapeutics Ltd.. (11/1/21). "Press Release: Amphista Therapeutics Appoints CBO, Beverley Carr". Cambridge....
- [2] Achilles Therapeutics plc. (4/6/21). "Press Release: Achilles Therapeutics Announces Closing of $175.5 Million Initial Public Offering". London....
- [3] Achilles Therapeutics plc. (3/30/21). "Press Release: Achilles Therapeutics Announces Pricing of Initial Public Offering". London....
- [4] Achilles Therapeutics plc. (3/1/21). "Press Release: Achilles Therapeutics Announces Filing of Registration Statement for Proposed Initial Public Offering in the United States". London....
- [5] Achilles Therapeutics Ltd.. (12/7/20). "Press Release: Achilles Therapeutics Appoints Lee M. Stern as VP, IR & External Communications". Stevenage....
- [6] Achilles Therapeutics Ltd.. (12/1/20). "Press Release: Achilles Therapeutics Appoints Robert Coutts as Chief Financial Officer". Stevenage....
- [7] Achilles Therapeutics Ltd.. (11/19/20). "Press Release: Achilles Therapeutics Raises £52.7 Million in an Oversubscribed Series C Financing to Further Advance the Development of Personalised T cell Therapies to Treat Solid Tumours". Stevenage....
- [8] Achilles Therapeutics Ltd.. (10/21/19). "Press Release: Achilles Therapeutics Appoints Beverley Carr as Chief Business Officer". Stevenage....
- [9] Achilles Therapeutics Ltd.. (9/3/19). "Press Release: Achilles Therapeutics Raises £100 Million in Oversubscribed Series B Financing". Stevenage....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top